co.don AG Expands Executive Board With Appointment Of Chief Financial Officer
Berlin, 12 May 2016 – The Supervisory Board of co.don AG expanded the Executive Board on 10 May 2016, appointing Mr Ralf M. Jakobs as an Executive Board member.
As the company's Chief Financial Officer (CFO), Mr Jakobs will be responsible for Human Resources and IT in addition to leading the finance function.
Mr Jakobs has many years of international capital market experience, with a focus on corporate finance, risk controlling, risk management and personnel development. He holds a diploma in business law and has extensive national and international management expertise.
The expansion of the Executive Board is another step in the commercialisation of the company; it creates the necessary management structures to lead the planned internationalisation of its business model.
About co.don® AG:
Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects.co.don condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 9,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO) More information is available at www.ihre-zellzuechter.de or www.codon.de
As the company's Chief Financial Officer (CFO), Mr Jakobs will be responsible for Human Resources and IT in addition to leading the finance function.
Mr Jakobs has many years of international capital market experience, with a focus on corporate finance, risk controlling, risk management and personnel development. He holds a diploma in business law and has extensive national and international management expertise.
The expansion of the Executive Board is another step in the commercialisation of the company; it creates the necessary management structures to lead the planned internationalisation of its business model.
About co.don® AG:
Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects.co.don condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 9,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO) More information is available at www.ihre-zellzuechter.de or www.codon.de